menu

Spotlight on the Rare & Challenging EGFR Exon 20 Insertion in NSCLC

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Spotlight on the Rare & Challenging EGFR Exon 20 Insertion in NSCLC

Program Information
Recommended

Program Information

ReachMD Healthcare Image
RestartResume

Explore how EGFR exon 20 insertion mutations impact patient outcomes, therapy, and more.

  • Sponsored by

  • Overview

    Exon 20 insertion mutations account for up to 10 percent of EGFR mutations and approximately 2 percent of all non-small cell lung cancer mutations. Although less common, EGFR mutations at exon 20 have an important impact on therapy selection. That’s why Dr. John Heymach speaks with Dr. Michelle Shiller about what those impacts are as well as the available therapies for patients with these mutations.

    All trademarks are the property of their respective owners.
    ©2021 Takeda Pharmaceuticals U.S.A., Inc. All rights reserved.
    December, 2021. VV-MEDMAT-56973

Schedule16 May 2022
Webpack App